
|Articles|October 22, 2012
FDA warns of serious blood disorder resulting from abuse of Opana ER
FDA has warned patients of thrombotic thrombocytopenic purpura (TTP), a serious blood disorder, resulting from misuse of oxymorphone hydrochloride extended-release tablets (Opana ER, Endo).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
New Study Finds Compounded GLP-1s Remain Robust Despite End of Shortages
2
ICER Report Finds GLP-1s Are Cost-Effective But Warns of Budget Strain
3
Postpartum Mothers Favor Bedtime Stopping Rule Over Stricter Chrononutrition Approaches
4
What’s Next for Pneumococcal Vaccination? An Expert Weighs In
5






























